10/31/14 CMN 42.40 Cantel Medical $CMN Hit a 52 week high of 42.92 Closing the day 10/31/14 at 42.40 +0.47 +1.12% With a day low of 42.16 and a total volume of 122,000.
CMN Recent Posts: http://investorshangout.com/Cantel-Medical-CMN-50561/
CMN Cantel Medical Recent Headline News
13.3% Return Seen to Date on SmarTrend Cantel Medical Call (CMN)
Comtex SmarTrend(R) - Wed Oct 29, 9:19AM CDT
SmarTrend identified an Uptrend for Cantel Medical (NYSE:CMN) on October 10th, 2014 at $36.38. In approximately 3 weeks, Cantel Medical has returned 13.35% as of today's recent price of $41.23.
CMN: 42.40 (+0.47)
New York Surgical Mask Manufacturer Responds to PPE Recommendations, Healthcare Worker Concerns
PR Newswire - Tue Oct 28, 7:30AM CDT
The CDC recently revised their Personal Protective Equipment (PPE) recommendations for healthcare workers caring for Ebola Virus Disease (EVD) patients to include the use of N95 or PAPR respirators and full coverage of all exposed skin. Emory Healthcare, a targeted treatment facility for EVD patients, also released their Healthcare Ebola Preparedness Protocols draft document http://www.emoryhealthcare.org/ebola-protocol...tocols.pdf. While the CDC recommendations are specific only to direct patient care of diagnosed EVD patients and exclude the use of medical face masks in this specific scenario, Emory's recommendations involve a broader set of EVD scenarios (Appendix 5; a "PPE Guidance Matrix for EVD"
, and specifically recommends the use of face masks in every situation, except during the care of a diagnosed, symptomatic EVD patient.
CMN: 42.40 (+0.47)
Cantel Medical Named to the Forbes 2014 List of the "100 Best Small Companies in America"
PR Newswire - Thu Oct 23, 7:30AM CDT
CANTEL MEDICAL CORP. (NYSE:CMN) announced today that for the third consecutive year, it was named to the Forbes list of the "100 Best Small Companies in America." The Company was ranked number 79 on the Forbes 2014 list.
CMN: 42.40 (+0.47)
Today's Strong And Under The Radar Stock: Cantel Medical (CMN)
at The Street - Wed Oct 08, 1:24PM CDT
Trade-Ideas LLC identified Cantel Medical (CMN) as a strong and under the radar candidate
CMN: 42.40 (+0.47)
Global Laboratory Filtration Market Outlook 2019: Pall Corporation and Merck Millipore Dominates the $2.53 Billion Industry
M2 - Mon Oct 06, 9:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gb4k5m/laboratory) has announced the addition of the "Laboratory Filtration Market by Technology, Product, Accessories & by End-User - Global Forecasts to 2019" report to their offering. The global laboratory filtration market is expected to grow at a strong CAGR during the forecast period of 2014-2019 and is estimated to be worth $2,532.6 million by 2019 The market is mainly driven by the increasing research activities in the pharmaceutical and biotechnology segments, and growing demand for biotech molecules for therapeutic and diagnostic applications and increasing purity requirements in end-user markets. However, technological developments cutting down the use of the membrane filtration technology may hamper the growth of the market to a certain extent. During the forecast period the microfiltration segment will continue to dominate the laboratory filtration market. Microfiltration segment is growing primarily due to increasing use of microfiltration membranes as prefilters to ultrafiltration and reverse osmosis processes. Furthermore, growing demand of filtration technologies in pharmaceutical and biopharmaceutical industries is also expected to drive the growth of the laboratory filtration market. By 2019, North America will be the largest share to the global laboratory filtration market, followed by Europe, Asia-Pacific, and RoW. Developed markets like North America and Europe are likely to grow at a lower CAGR as compared to the Asia-Pacific market. The Asia Pacific region is expected to have the fastest market growth during the forecast period, largely driven by the increasing research funding form government and private investors and growing number of research laboratories. Pall Corporation (U.S.) and Merck Millipore (U.S.) are the leading players, together accounting for around 35% to 40% share in the global laboratory filtration market in 2013. Pall Corporation has a diversified product portfolio, which includes a wide range of filtration products including filter capsules, membrane filters, filter funnels, filter holders, syringe filters, and laboratory water purification systems. The company has an extensive experience and expertise in filtration technology. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Global Laboratory Filtration Market, By Technology 8 Global Laboratory Filtration Equipment Market, By Type 9 Global Lab Filtration Accessories Market, By Type 10 Global Laboratory Filtration Market, By End User 11 Laboratory Filtration Market, By Geography 12 Competitive Landscape 13 Company Profiles - 3M Company - Cantel Medical Corp. - General Electric Company - Merck Millipore - Pall Corporation - Sartorius Group - Sigma-Aldrich Corporation - Sterlitech Corporation - Thermo Fisher Scientific, Inc. - Veolia Water Technologies Corporation For more information visit http://www.researchandmarkets.com/research/gb4k5m/laboratory
MMM: 153.77 (+1.67), GE: 25.81 (+0.14), PLL: 91.42 (+0.50), SIAL: 135.91 (+0.33), MRK: 57.94 (+0.63), CMN: 42.40 (+0.47)
Cantel Medical Reports 15% Sales Increase With EPS Of $0.26 Vs. $0.25 For Fourth Quarter
PR Newswire - Mon Sep 29, 7:30AM CDT
CANTEL MEDICAL CORP. (NYSE: CMN) reported net income of $10,705,000, or $0.26 per diluted share, on a 15% increase in sales to a record $131,377,000 for the fourth quarter ended July 31, 2014, inclusive of $0.02 for charges related to acquisition and CFO retirement costs. This compares with net income of $10,213,000, or $0.25 per diluted share, on sales of $113,973,000 for the fourth quarter ended July 31, 2013.
CMN: 42.40 (+0.47)
Cantel Medical Corp. to Host Fourth Quarter and Fiscal 2014 Earnings Webcast Live on Monday, September 29, 2014
ACCESSWIRE - Fri Sep 26, 3:13PM CDT
LITTLE FALLS, NJ / ACCESSWIRE / September 26, 2014 / Cantel Medical Corp. (NYSE:CMN) will host a live webcast to discuss the results of the fourth quarter and fiscal 2014, to be held Monday, September 29, 2014 at 11:00 AM Eastern Time.
CMN: 42.40 (+0.47)
Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014
PR Newswire - Mon Sep 22, 7:30AM CDT
LITTLE FALLS, N.J., Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN) will release the results for its fourth quarter and fiscal 2014 ended July 31, 2014 on Monday, September 29 before the market opens, and hold a conference call to discuss the results at 11:00 AM ET. Participating in the call will be Charles M. Diker, Chairman; Andrew A. Krakauer, President and CEO; Jorgen B. Hansen, Executive Vice President and COO; Craig A. Sheldon, Senior Vice President, CFO and Treasurer; and Seth Yellin, Senior Vice President-Corporate Development.
CMN: 42.40 (+0.47)
Global Dialysis Products and Services (Hemodialysis Products, Peritoneal Dialysis Products
M2 - Thu Sep 11, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c8vw2r/dialysis_products) has announced the addition of the "Dialysis Products and Services Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. According to the National Institutes of Health, the worldwide number of patients with chronic kidney disease is rising rapidly and is expected to rise by approximately 5% to 8% annually. Increasing prevalence of diabetes and hypertension are the two primary causes of end stage renal disease in major developing countries like China, Brazil and India and is also contributing to the growth of overall dialysis products and services market. According to the American Kidney Fund, diabetes and hypertension are responsible for 38.4% and 25% of all cases of kidney failures, respectively. Similarly, increasing geriatric population and low preference by patients above 65 years of age to opt for kidney transplant is also driving the growth of dialysis products and services market. According to the Australian Institute of Health and Welfare, the proportion of people opting for kidney transplantation decreases with age. Moreover, increasing awareness about peritoneal dialysis is expected to boost the growth of the market in the near future. The global dialysis products and services market is segmented by type of procedures and type of services. The procedures market is further segmented into hemodialysis and peritoneal dialysis. Further, the hemodialysis segment (HD) is classified into HD machine, dialyzer, access products/catheters, bloodlines, concentrates and others, which include water treatment systems and fistula needles. Hemodialysis, being the oldest and most preferred technique for dialysis procedure, Hemodialysis machines captures the largest share, of the total market in 2013. The segment is expected to lead the market during the forecast period from 2014 to 2020. Similarly, peritoneal dialysis (PD) segment is classified into concentrates/dialysate, PD machines, catheters, and transfer sets. Among these, the PD concentrates/dialysate segment is accounted for largest market share in 2013 and is expected to grow at an attractive higher growth rate during the forecast period from 2014 to 2020. The major factors responsible for the significant growth of this segment are increase in the number of patients preferring peritoneal dialysis, and rising demand of patients to be dialyzed overnight with the aid of peritoneal dialysis. Dialysis Products and Services Market, by Product type: Hemodialysis - HD Machines - Dialyzers - HD Access Products/Catheters - Bloodlines - HD Concentrates/Dialysate - Others (Water Treatment System, Fistula Needles) Peritoneal Dialysis - Concentrates/Dialysate - PD Machines - PD Catheters - PD Transfer Sets Dialysis Products and Services Market, by Type of Services: - In-center Dialysis - Home Dialysis Companies Mentioned - Asahi Kasei Corporation - B. Braun Melsungen AG - Baxter International, Inc. - C. R. Bard, Inc. - Cantel Medical Corporation - Covidien plc - DaVita Healthcare Partners, Inc. - Fresenius SE & Co. KGaA - Kawasumi Laboratories, Inc. - Medical Components, Inc. - Nikkiso Co., Ltd. - Nipro Corporation - NxStage Medical, Inc. - Rockwell Medical Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/c8...s_products
NXTM: 15.16 (+0.03), BAX: 70.14 (+0.08), RMTI: 8.72 (-0.66), CMN: 42.40 (+0.47)
Cantel Medical Subsidiary - MEDIVATORS ENDOCUFF(TM) Overtube Improves Adenoma and Polyp Detection
PR Newswire - Wed Sep 10, 7:30AM CDT
The ENDOCUFF(TM) Endoscopic Overtube now provided by MEDIVATORS, a leading medical device company with over thirty years of experience in endoscopy technology, substantially improves adenoma and polyp detection during colonoscopies according to two separate industry studies. The ENDOCUFF device is a small disposable plastic over-tube with soft flexible projections. Placed over the tip of the endoscope, the device helps increase control and flatten colonic folds to improve mucosa examination.
CMN: 42.40 (+0.47)
Cantel Medical Completes Acquisition Of PuriCore International Ltd.
PR Newswire - Tue Jul 01, 7:30AM CDT
CANTEL MEDICAL CORP. (NYSE:CMN), today announced that the company has successfully completed the acquisition of PuriCore International Limited., a wholly-owned subsidiary of PuriCore plc (LSE: PURI). The transaction further enhances Cantel Medical's global leadership of automated endoscope reprocessing and provides the company with additional resources and capabilities to execute on its broader international strategy. PuriCore International Limited will be renamed Cantel Medical (UK) Limited and will be reported as part of our Endoscopy segment.
CMN: 42.40 (+0.47)
Medivators Launches JET PREP(TM) Device to Improve Polyp Detection
PR Newswire - Mon Jun 23, 2:10PM CDT
Medivators Inc., a Cantel Medical company and a leading medical device manufacturer with over thirty years in endoscopy technology, announces the debut of the JET PREP(TM) Endoscopic Flushing Device, a novel irrigation and suction device that clears and removes debris and obstructions from the colon during a colonoscopy, resulting in improved visualization of the gastrointestinal tract and increased polyp detection.
CMN: 42.40 (+0.47)
Cantel Medical Board Of Directors Authorizes Regular Semiannual Dividend
PR Newswire - Thu Jun 19, 8:35AM CDT
CANTEL MEDICAL CORP. (NYSE: CMN) announced today that its Board of Directors authorized a regular semiannual cash dividend of $0.045 per outstanding share of the Company's Common Stock. The dividend is payable on July 31, 2014 to shareholders of record at the close of business on July 17, 2014.
CMN: 42.40 (+0.47)
Healthcare Companies Report Clinical Study Results, Financial Results and Stock Summaries - Analyst Notes on Endocyte, Ophthotech, AcelRx Pharmaceuticals, bluebird bio, and Cantel Medical
PR Newswire - Wed Mar 26, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Endocyte, Inc. (NASDAQ: ECYT), Ophthotech Corporation (NASDAQ: OPHT), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), bluebird bio, Inc. (NASDAQ: BLUE), and Cantel Medical Corp. (NYSE: CMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
BLUE: 41.99 (+0.70), ACRX: 6.63 (-0.31), ECYT: 5.99 (-0.23), OPHT: 41.72 (-0.09), CMN: 42.40 (+0.47)
Nephros and Mar Cor Purification Announce Distribution Agreement
PR Newswire - Tue Mar 11, 3:10PM CDT
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and Mar Cor Purification, a wholly owned subsidiary of Cantel Medical Corp., announced today that the companies have signed a non-exclusive distributor agreement to distribute Nephros's dialysis ultrafilters to U.S. and Canadian dialysis clinics.
CMN: 42.40 (+0.47)
Cantel Medical Reports EPS Of $0.27 vs. $0.25 On 12% Sales Increase For Second Quarter Ended January 31, 2014
PR Newswire - Tue Mar 11, 7:00AM CDT
CANTEL MEDICAL CORP. (NYSE:CMN) reported net income of $11,126,000, or $0.27 per diluted share, on a 12% increase in sales to a record $119,042,000 for the second quarter ended January 31, 2014. This compares with net income of $10,452,000, or $0.25 per diluted share, on sales of $106,363,000 for the second quarter ended January 31, 2013. For the six months ended January 31, 2014, the Company reported record net income of $22,311,000, or $0.54 per diluted share, on a 15% increase in sales to a record $237,314,000. This compares with net income of $20,028,000, or $0.49 per diluted share, on sales of $206,044,000 for the six months ended January 31, 2013. Results for the prior year's second quarter and six months ended January 31, 2013 include $0.01 in net favorable adjustments related to acquisition accounting fair value adjustments partially offset by severance and recruiting costs.
CMN: 42.40 (+0.47)
Cantel Medical Corp. to Host Second Quarter Earnings Webcast Live on Tuesday, March 11, 2014
ACCESSWIRE - Mon Mar 10, 1:11PM CDT
LITTLE FALLS, NJ / ACCESSWIRE / March 10, 2014 / Cantel Medical Corp. (CMN) will host a live webcast to discuss the results of the second quarter 2014, to be held Tuesday, March 11, 2014 at 11:00 AM Eastern Time.
CMN: 42.40 (+0.47)
Sterilization Equipment and Disinfectants Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Fri Mar 07, 3:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/z899cm/sterilization) has announced the addition of the "Sterilization Equipment and Disinfectants Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering 'Sterilization Equipment and Disinfectants Market (By Sterilization Equipment Type - Heat Sterilization, Low Temperature Sterilization, Filtration Sterilization and Radiation Sterilization,By Disinfectants Type-Low, Intermediate and High level and Oxidizing and Non-Oxidizing and By Applications- Medical Devices, Pharmaceuticals and Life-Sciences) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019' "Sterilization equipment and disinfectants are essential procedures for infection control in healthcare facilities such as hospitals, clinics and laboratories. Increase in hospital acquired infections has compelled medical professionals to take strict regulatory actions to cure these infections with the use of various sterilization equipment and disinfectants. This factor will trigger the growth of sterilization equipment and disinfectants market during the forecast period. In addition, rise in geriatric population and increase in the number of surgeries performed at hospitals and clinics will further drive the growth of this market. The market for sterilization equipment can be segmented as: by product (heat, low temperature, radiation and filtration sterilization) and by application (life sciences, medical devices and pharmaceuticals). The disinfectants market has been segmented based on types (low, intermediate and high level, oxidizing and non-oxidizing disinfectants). The report includes market estimations in terms of revenue (USD million) for the global sterilization equipment and disinfectants market for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for all the aforementioned segments and sub segments. In addition, current market trends and recent developments have been taken into consideration while determining the growth rate of the global sterilization equipment and disinfectants market. Key Topics Covered: Introduction Executive Summary Market Overview Global Sterilization Equipment Market, By Product, 2011 - 2019 (USD Million) Global Disinfectants Market, By Type, 2011 - 2019 (USD Million) Global Sterilization Equipment and Disinfectants Market, By Applications, 2011 - 2019 (USD Million) Global Sterilization Equipment and Disinfectants Market, by Geography, 2011 - 2019 (USD Million) Recommendations Company Profiles Companies Mentioned - 3M - Advanced Sterilization Products Services, Inc. - Belimed AG - Cantel Medical Corp. - CISA Group - Getinge Group - Kimberley-Clark Corporation - Matachana Group - Nordion, Inc. - SAKURA SI CO., LTD. - STERIS Corporation - Synergy Health Plc - TSO3, Inc. For more information visit http://www.researchandmarkets.com/research/z8...rilization About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
STE: 61.80 (+0.96), NDZ: 12.99 (-0.01), CMN: 42.40 (+0.47)
Cantel Medical Corp. to Present at the Sidoti & Company LLC 18th Annual Emerging Growth Institutional Investor Forum
PR Newswire - Thu Mar 06, 11:44AM CST
CANTEL MEDICAL CORP. (NYSE:CMN) announced today that Andrew A. Krakauer, President & CEO, will be presenting at the Sidoti & Company, LLC 18th Annual Emerging Growth Institutional Investor Forum. The formal presentation is scheduled for 10:00 AM ET on Monday, March 17, 2014 at the Grand Hyatt Hotel, New York. In addition, Mr. Krakauer and Seth Yellin, Senior VP-Corporate Development, will be available for separate one-on-one meetings during the day.
CMN: 42.40 (+0.47)
CMN Recent Posts: http://investorshangout.com/Cantel-Medical-CMN-50561/
CMN Cantel Medical Recent Headline News
13.3% Return Seen to Date on SmarTrend Cantel Medical Call (CMN)
Comtex SmarTrend(R) - Wed Oct 29, 9:19AM CDT
SmarTrend identified an Uptrend for Cantel Medical (NYSE:CMN) on October 10th, 2014 at $36.38. In approximately 3 weeks, Cantel Medical has returned 13.35% as of today's recent price of $41.23.
CMN: 42.40 (+0.47)
New York Surgical Mask Manufacturer Responds to PPE Recommendations, Healthcare Worker Concerns
PR Newswire - Tue Oct 28, 7:30AM CDT
The CDC recently revised their Personal Protective Equipment (PPE) recommendations for healthcare workers caring for Ebola Virus Disease (EVD) patients to include the use of N95 or PAPR respirators and full coverage of all exposed skin. Emory Healthcare, a targeted treatment facility for EVD patients, also released their Healthcare Ebola Preparedness Protocols draft document http://www.emoryhealthcare.org/ebola-protocol...tocols.pdf. While the CDC recommendations are specific only to direct patient care of diagnosed EVD patients and exclude the use of medical face masks in this specific scenario, Emory's recommendations involve a broader set of EVD scenarios (Appendix 5; a "PPE Guidance Matrix for EVD"
, and specifically recommends the use of face masks in every situation, except during the care of a diagnosed, symptomatic EVD patient. CMN: 42.40 (+0.47)
Cantel Medical Named to the Forbes 2014 List of the "100 Best Small Companies in America"
PR Newswire - Thu Oct 23, 7:30AM CDT
CANTEL MEDICAL CORP. (NYSE:CMN) announced today that for the third consecutive year, it was named to the Forbes list of the "100 Best Small Companies in America." The Company was ranked number 79 on the Forbes 2014 list.
CMN: 42.40 (+0.47)
Today's Strong And Under The Radar Stock: Cantel Medical (CMN)
at The Street - Wed Oct 08, 1:24PM CDT
Trade-Ideas LLC identified Cantel Medical (CMN) as a strong and under the radar candidate
CMN: 42.40 (+0.47)
Global Laboratory Filtration Market Outlook 2019: Pall Corporation and Merck Millipore Dominates the $2.53 Billion Industry
M2 - Mon Oct 06, 9:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gb4k5m/laboratory) has announced the addition of the "Laboratory Filtration Market by Technology, Product, Accessories & by End-User - Global Forecasts to 2019" report to their offering. The global laboratory filtration market is expected to grow at a strong CAGR during the forecast period of 2014-2019 and is estimated to be worth $2,532.6 million by 2019 The market is mainly driven by the increasing research activities in the pharmaceutical and biotechnology segments, and growing demand for biotech molecules for therapeutic and diagnostic applications and increasing purity requirements in end-user markets. However, technological developments cutting down the use of the membrane filtration technology may hamper the growth of the market to a certain extent. During the forecast period the microfiltration segment will continue to dominate the laboratory filtration market. Microfiltration segment is growing primarily due to increasing use of microfiltration membranes as prefilters to ultrafiltration and reverse osmosis processes. Furthermore, growing demand of filtration technologies in pharmaceutical and biopharmaceutical industries is also expected to drive the growth of the laboratory filtration market. By 2019, North America will be the largest share to the global laboratory filtration market, followed by Europe, Asia-Pacific, and RoW. Developed markets like North America and Europe are likely to grow at a lower CAGR as compared to the Asia-Pacific market. The Asia Pacific region is expected to have the fastest market growth during the forecast period, largely driven by the increasing research funding form government and private investors and growing number of research laboratories. Pall Corporation (U.S.) and Merck Millipore (U.S.) are the leading players, together accounting for around 35% to 40% share in the global laboratory filtration market in 2013. Pall Corporation has a diversified product portfolio, which includes a wide range of filtration products including filter capsules, membrane filters, filter funnels, filter holders, syringe filters, and laboratory water purification systems. The company has an extensive experience and expertise in filtration technology. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Global Laboratory Filtration Market, By Technology 8 Global Laboratory Filtration Equipment Market, By Type 9 Global Lab Filtration Accessories Market, By Type 10 Global Laboratory Filtration Market, By End User 11 Laboratory Filtration Market, By Geography 12 Competitive Landscape 13 Company Profiles - 3M Company - Cantel Medical Corp. - General Electric Company - Merck Millipore - Pall Corporation - Sartorius Group - Sigma-Aldrich Corporation - Sterlitech Corporation - Thermo Fisher Scientific, Inc. - Veolia Water Technologies Corporation For more information visit http://www.researchandmarkets.com/research/gb4k5m/laboratory
MMM: 153.77 (+1.67), GE: 25.81 (+0.14), PLL: 91.42 (+0.50), SIAL: 135.91 (+0.33), MRK: 57.94 (+0.63), CMN: 42.40 (+0.47)
Cantel Medical Reports 15% Sales Increase With EPS Of $0.26 Vs. $0.25 For Fourth Quarter
PR Newswire - Mon Sep 29, 7:30AM CDT
CANTEL MEDICAL CORP. (NYSE: CMN) reported net income of $10,705,000, or $0.26 per diluted share, on a 15% increase in sales to a record $131,377,000 for the fourth quarter ended July 31, 2014, inclusive of $0.02 for charges related to acquisition and CFO retirement costs. This compares with net income of $10,213,000, or $0.25 per diluted share, on sales of $113,973,000 for the fourth quarter ended July 31, 2013.
CMN: 42.40 (+0.47)
Cantel Medical Corp. to Host Fourth Quarter and Fiscal 2014 Earnings Webcast Live on Monday, September 29, 2014
ACCESSWIRE - Fri Sep 26, 3:13PM CDT
LITTLE FALLS, NJ / ACCESSWIRE / September 26, 2014 / Cantel Medical Corp. (NYSE:CMN) will host a live webcast to discuss the results of the fourth quarter and fiscal 2014, to be held Monday, September 29, 2014 at 11:00 AM Eastern Time.
CMN: 42.40 (+0.47)
Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014
PR Newswire - Mon Sep 22, 7:30AM CDT
LITTLE FALLS, N.J., Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN) will release the results for its fourth quarter and fiscal 2014 ended July 31, 2014 on Monday, September 29 before the market opens, and hold a conference call to discuss the results at 11:00 AM ET. Participating in the call will be Charles M. Diker, Chairman; Andrew A. Krakauer, President and CEO; Jorgen B. Hansen, Executive Vice President and COO; Craig A. Sheldon, Senior Vice President, CFO and Treasurer; and Seth Yellin, Senior Vice President-Corporate Development.
CMN: 42.40 (+0.47)
Global Dialysis Products and Services (Hemodialysis Products, Peritoneal Dialysis Products
M2 - Thu Sep 11, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c8vw2r/dialysis_products) has announced the addition of the "Dialysis Products and Services Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. According to the National Institutes of Health, the worldwide number of patients with chronic kidney disease is rising rapidly and is expected to rise by approximately 5% to 8% annually. Increasing prevalence of diabetes and hypertension are the two primary causes of end stage renal disease in major developing countries like China, Brazil and India and is also contributing to the growth of overall dialysis products and services market. According to the American Kidney Fund, diabetes and hypertension are responsible for 38.4% and 25% of all cases of kidney failures, respectively. Similarly, increasing geriatric population and low preference by patients above 65 years of age to opt for kidney transplant is also driving the growth of dialysis products and services market. According to the Australian Institute of Health and Welfare, the proportion of people opting for kidney transplantation decreases with age. Moreover, increasing awareness about peritoneal dialysis is expected to boost the growth of the market in the near future. The global dialysis products and services market is segmented by type of procedures and type of services. The procedures market is further segmented into hemodialysis and peritoneal dialysis. Further, the hemodialysis segment (HD) is classified into HD machine, dialyzer, access products/catheters, bloodlines, concentrates and others, which include water treatment systems and fistula needles. Hemodialysis, being the oldest and most preferred technique for dialysis procedure, Hemodialysis machines captures the largest share, of the total market in 2013. The segment is expected to lead the market during the forecast period from 2014 to 2020. Similarly, peritoneal dialysis (PD) segment is classified into concentrates/dialysate, PD machines, catheters, and transfer sets. Among these, the PD concentrates/dialysate segment is accounted for largest market share in 2013 and is expected to grow at an attractive higher growth rate during the forecast period from 2014 to 2020. The major factors responsible for the significant growth of this segment are increase in the number of patients preferring peritoneal dialysis, and rising demand of patients to be dialyzed overnight with the aid of peritoneal dialysis. Dialysis Products and Services Market, by Product type: Hemodialysis - HD Machines - Dialyzers - HD Access Products/Catheters - Bloodlines - HD Concentrates/Dialysate - Others (Water Treatment System, Fistula Needles) Peritoneal Dialysis - Concentrates/Dialysate - PD Machines - PD Catheters - PD Transfer Sets Dialysis Products and Services Market, by Type of Services: - In-center Dialysis - Home Dialysis Companies Mentioned - Asahi Kasei Corporation - B. Braun Melsungen AG - Baxter International, Inc. - C. R. Bard, Inc. - Cantel Medical Corporation - Covidien plc - DaVita Healthcare Partners, Inc. - Fresenius SE & Co. KGaA - Kawasumi Laboratories, Inc. - Medical Components, Inc. - Nikkiso Co., Ltd. - Nipro Corporation - NxStage Medical, Inc. - Rockwell Medical Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/c8...s_products
NXTM: 15.16 (+0.03), BAX: 70.14 (+0.08), RMTI: 8.72 (-0.66), CMN: 42.40 (+0.47)
Cantel Medical Subsidiary - MEDIVATORS ENDOCUFF(TM) Overtube Improves Adenoma and Polyp Detection
PR Newswire - Wed Sep 10, 7:30AM CDT
The ENDOCUFF(TM) Endoscopic Overtube now provided by MEDIVATORS, a leading medical device company with over thirty years of experience in endoscopy technology, substantially improves adenoma and polyp detection during colonoscopies according to two separate industry studies. The ENDOCUFF device is a small disposable plastic over-tube with soft flexible projections. Placed over the tip of the endoscope, the device helps increase control and flatten colonic folds to improve mucosa examination.
CMN: 42.40 (+0.47)
Cantel Medical Completes Acquisition Of PuriCore International Ltd.
PR Newswire - Tue Jul 01, 7:30AM CDT
CANTEL MEDICAL CORP. (NYSE:CMN), today announced that the company has successfully completed the acquisition of PuriCore International Limited., a wholly-owned subsidiary of PuriCore plc (LSE: PURI). The transaction further enhances Cantel Medical's global leadership of automated endoscope reprocessing and provides the company with additional resources and capabilities to execute on its broader international strategy. PuriCore International Limited will be renamed Cantel Medical (UK) Limited and will be reported as part of our Endoscopy segment.
CMN: 42.40 (+0.47)
Medivators Launches JET PREP(TM) Device to Improve Polyp Detection
PR Newswire - Mon Jun 23, 2:10PM CDT
Medivators Inc., a Cantel Medical company and a leading medical device manufacturer with over thirty years in endoscopy technology, announces the debut of the JET PREP(TM) Endoscopic Flushing Device, a novel irrigation and suction device that clears and removes debris and obstructions from the colon during a colonoscopy, resulting in improved visualization of the gastrointestinal tract and increased polyp detection.
CMN: 42.40 (+0.47)
Cantel Medical Board Of Directors Authorizes Regular Semiannual Dividend
PR Newswire - Thu Jun 19, 8:35AM CDT
CANTEL MEDICAL CORP. (NYSE: CMN) announced today that its Board of Directors authorized a regular semiannual cash dividend of $0.045 per outstanding share of the Company's Common Stock. The dividend is payable on July 31, 2014 to shareholders of record at the close of business on July 17, 2014.
CMN: 42.40 (+0.47)
Healthcare Companies Report Clinical Study Results, Financial Results and Stock Summaries - Analyst Notes on Endocyte, Ophthotech, AcelRx Pharmaceuticals, bluebird bio, and Cantel Medical
PR Newswire - Wed Mar 26, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Endocyte, Inc. (NASDAQ: ECYT), Ophthotech Corporation (NASDAQ: OPHT), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), bluebird bio, Inc. (NASDAQ: BLUE), and Cantel Medical Corp. (NYSE: CMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
BLUE: 41.99 (+0.70), ACRX: 6.63 (-0.31), ECYT: 5.99 (-0.23), OPHT: 41.72 (-0.09), CMN: 42.40 (+0.47)
Nephros and Mar Cor Purification Announce Distribution Agreement
PR Newswire - Tue Mar 11, 3:10PM CDT
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and Mar Cor Purification, a wholly owned subsidiary of Cantel Medical Corp., announced today that the companies have signed a non-exclusive distributor agreement to distribute Nephros's dialysis ultrafilters to U.S. and Canadian dialysis clinics.
CMN: 42.40 (+0.47)
Cantel Medical Reports EPS Of $0.27 vs. $0.25 On 12% Sales Increase For Second Quarter Ended January 31, 2014
PR Newswire - Tue Mar 11, 7:00AM CDT
CANTEL MEDICAL CORP. (NYSE:CMN) reported net income of $11,126,000, or $0.27 per diluted share, on a 12% increase in sales to a record $119,042,000 for the second quarter ended January 31, 2014. This compares with net income of $10,452,000, or $0.25 per diluted share, on sales of $106,363,000 for the second quarter ended January 31, 2013. For the six months ended January 31, 2014, the Company reported record net income of $22,311,000, or $0.54 per diluted share, on a 15% increase in sales to a record $237,314,000. This compares with net income of $20,028,000, or $0.49 per diluted share, on sales of $206,044,000 for the six months ended January 31, 2013. Results for the prior year's second quarter and six months ended January 31, 2013 include $0.01 in net favorable adjustments related to acquisition accounting fair value adjustments partially offset by severance and recruiting costs.
CMN: 42.40 (+0.47)
Cantel Medical Corp. to Host Second Quarter Earnings Webcast Live on Tuesday, March 11, 2014
ACCESSWIRE - Mon Mar 10, 1:11PM CDT
LITTLE FALLS, NJ / ACCESSWIRE / March 10, 2014 / Cantel Medical Corp. (CMN) will host a live webcast to discuss the results of the second quarter 2014, to be held Tuesday, March 11, 2014 at 11:00 AM Eastern Time.
CMN: 42.40 (+0.47)
Sterilization Equipment and Disinfectants Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Fri Mar 07, 3:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/z899cm/sterilization) has announced the addition of the "Sterilization Equipment and Disinfectants Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering 'Sterilization Equipment and Disinfectants Market (By Sterilization Equipment Type - Heat Sterilization, Low Temperature Sterilization, Filtration Sterilization and Radiation Sterilization,By Disinfectants Type-Low, Intermediate and High level and Oxidizing and Non-Oxidizing and By Applications- Medical Devices, Pharmaceuticals and Life-Sciences) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019' "Sterilization equipment and disinfectants are essential procedures for infection control in healthcare facilities such as hospitals, clinics and laboratories. Increase in hospital acquired infections has compelled medical professionals to take strict regulatory actions to cure these infections with the use of various sterilization equipment and disinfectants. This factor will trigger the growth of sterilization equipment and disinfectants market during the forecast period. In addition, rise in geriatric population and increase in the number of surgeries performed at hospitals and clinics will further drive the growth of this market. The market for sterilization equipment can be segmented as: by product (heat, low temperature, radiation and filtration sterilization) and by application (life sciences, medical devices and pharmaceuticals). The disinfectants market has been segmented based on types (low, intermediate and high level, oxidizing and non-oxidizing disinfectants). The report includes market estimations in terms of revenue (USD million) for the global sterilization equipment and disinfectants market for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for all the aforementioned segments and sub segments. In addition, current market trends and recent developments have been taken into consideration while determining the growth rate of the global sterilization equipment and disinfectants market. Key Topics Covered: Introduction Executive Summary Market Overview Global Sterilization Equipment Market, By Product, 2011 - 2019 (USD Million) Global Disinfectants Market, By Type, 2011 - 2019 (USD Million) Global Sterilization Equipment and Disinfectants Market, By Applications, 2011 - 2019 (USD Million) Global Sterilization Equipment and Disinfectants Market, by Geography, 2011 - 2019 (USD Million) Recommendations Company Profiles Companies Mentioned - 3M - Advanced Sterilization Products Services, Inc. - Belimed AG - Cantel Medical Corp. - CISA Group - Getinge Group - Kimberley-Clark Corporation - Matachana Group - Nordion, Inc. - SAKURA SI CO., LTD. - STERIS Corporation - Synergy Health Plc - TSO3, Inc. For more information visit http://www.researchandmarkets.com/research/z8...rilization About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
STE: 61.80 (+0.96), NDZ: 12.99 (-0.01), CMN: 42.40 (+0.47)
Cantel Medical Corp. to Present at the Sidoti & Company LLC 18th Annual Emerging Growth Institutional Investor Forum
PR Newswire - Thu Mar 06, 11:44AM CST
CANTEL MEDICAL CORP. (NYSE:CMN) announced today that Andrew A. Krakauer, President & CEO, will be presenting at the Sidoti & Company, LLC 18th Annual Emerging Growth Institutional Investor Forum. The formal presentation is scheduled for 10:00 AM ET on Monday, March 17, 2014 at the Grand Hyatt Hotel, New York. In addition, Mr. Krakauer and Seth Yellin, Senior VP-Corporate Development, will be available for separate one-on-one meetings during the day.
CMN: 42.40 (+0.47)
